MarketResearch.biz delivers in-depth insights on the global diabetic neuropathy market in its upcoming report titled, “Global Diabetic Neuropathy Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global diabetic neuropathy market is estimated to register a CAGR of XXX% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global diabetic neuropathy market report has been segmented on the basis of disorder type, treatment, and region.
Diabetes is a chronic metabolic disorder that has affected both developed and developing countries. About 60 to 70 percent of people with diabetes have some form of neuropathy. Diabetic neuropathies are the nerve disorders caused by diabetes. Diabetic neuropathy damages the nerve throughout the body and can occur in every organ system, including the digestive tract, heart, and sex organs. Depending on the affected nerves, symptoms of diabetic neuropathy are pain, numbness, problems in digestive system, urinary tract, blood vessels and heart. The highest rates of neuropathy are found among people who have had diabetes for at least 25 years. Diagnosis of diabetic neuropathy is usually done by a clinical examination. Prevention of diabetic neuropathies focuses on glucose control and lifestyle modifications.
Increasing incidence and prevalence of diabetes and growing complications associated with diabetes such as blindness and nerve damage are major factors driving growth of the global diabetic neuropathy market. In addition, increasing number of geriatric population globally, sedentary lifestyle, urbanization associated with changes in eating habits, genetic composition, increasing incidence of chronic disease such as obesity, cardiovascular disease etc. are other major factors expected to boost growth of the global diabetic neuropathy market. High cost associated with the treatment of neuropathy is expected to challenge growth of the global diabetic neuropathy market.
National Institute of Neurological Disorders and Stroke (NINDS) are funding for research activities on neuropathy. Governments and various NGO’s in various countries are taking initiatives to spread awareness regarding prevention and control of diabetic neuropathy.
North America market dominates the global market of diabetic neuropathy, owing to increasing incidence of diabetes and associated disorders. Nearly 20 million people are affected by diabetic neuropathy in US. Asia Pacific diabetic neuropathy market is expected to register highest CAGR in terms of revenue owing to hectic lifestyle leading to no workout time, unhealthy eating habits.
Global Diabetic Neuropathy Market Segmentation:
Segmentation on the basis of disorder type:
- Peripheral neuropathy
- Autonomic neuropathy
- Proximal neuropathy
- Focal neuropathy
Segmentation on the basis of treatment:
Segmentation on the basis of region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Pfizer Inc.
- Eli Lilly and Company
- Actavis Pharma, Inc.
- Cephalon, Inc.
- Meda Pharma GmbH
- GlaxoSmithKline plc
- NeuroMetrix, Inc.
- Johnson & Johnson Inc.
- Boehringer Ingelheim GmbH
- Astellas Pharma Inc.
Request for TOC
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!